4D Molecular Therapeutics Inc. (4DMT) and Arbor Biotechnologies Inc. have established a strategic partnership focused on advancing new AAV-based gene-editing therapies for central nervous system (CNS) diseases with high unmet medical need in both rare and common disease populations.

Suzhou Ribo Life Science Co. Ltd. and Ribocure AB have entered into a collaboration with Boehringer Ingelheim Pharma GmbH & Co. KG to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).

Medilink Therapeutics (Suzhou) Co. Ltd. has entered into a worldwide collaboration and license agreement with F. Hoffmann-La Roche Ltd. for the development of YL-211, a next-generation antibody-drug conjugate candidate targeting proto-oncogene c-Met for solid tumors.

Voyager Therapeutics Inc. has entered into a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG, to advance potential gene therapies for Huntington’s disease and spinal muscular atrophy (SMA).

Elpiscience Biopharma Ltd. and Astellas Pharma Inc. have announced a research collaboration and license agreement for two novel bispecific macrophage engagers – ES-019 and another program.

Biocytogen Pharmaceuticals Co. Ltd. and Ctm Biotech Co. Ltd. have reported progress in the development of a trispecific T-cell engager for an intracellular target.

Fauna Bio Inc. has signed a multi-year agreement with Eli Lilly and Co. to apply Fauna’s Convergence artificial intelligence (AI) platform to support preclinical drug discovery efforts in obesity.

Innovent Biologics Inc. and Sanegene Bio USA Inc. (Sanegenebio) have announced they have entered into a collaboration agreement to co-develop SGB-3908, an siRNA drug candidate targeting angiotensinogen (AGT) for the treatment of hypertension.